In addition, combination therapy of BRAF inhibitors with allosteric MEK1 and MEK2 inhibitors are also in clinical trials and have been approved for treatment for BRAF mutant melanomas [7, 13, 28, 30, 31]. Here, MAP2K2 is linked to melanoma.